Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repatha for Cardiac Allograft Vasculopathy Prevention
NCT03734211Phase 3Completed
- Start
- Jun 2019
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 3 trial of evolocumab in cardiac allograft vasculopathy (CAV). Started Jun 2019; status: completed.
02
Drugs
evolocumab
03
Conditions
cardiac allograft vasculopathy (CAV)
Beyond the preview
Go deeper on NCT03734211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03734211.